© 2026 Optics and Photonics at Nottingham
43%
56.3%
8.8%
£5m+
Data for 2020-2025 from SciVal
Cardenas, Ryan P; Zyoud, Ahmad; McIntyre, Alan; Alberio, Ramiro; Mongan, Nigel P; Allegrucci, Cinzia
NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2 Journal Article
In: Stem Cell Res. Ther., vol. 15, no. 1, pp. 128, 2024.
Abstract | Links | Altmetric | Tags: Differentiation, MIR-9, NANOG, Pluripotency, stemness, Testicular germ cell tumours
@article{Cardenas2024-ev,
title = {NANOG controls testicular germ cell tumour stemness through regulation of MIR9-2},
author = {Ryan P Cardenas and Ahmad Zyoud and Alan McIntyre and Ramiro Alberio and Nigel P Mongan and Cinzia Allegrucci},
doi = {10.1186/s13287-024-03724-1},
year = {2024},
date = {2024-05-01},
urldate = {2024-05-01},
journal = {Stem Cell Res. Ther.},
volume = {15},
number = {1},
pages = {128},
publisher = {Springer Science and Business Media LLC},
abstract = {BACKGROUND: Testicular germ cell tumours (TGCTs) represent a
clinical challenge; they are most prevalent in young individuals
and are triggered by molecular mechanisms that are not fully
understood. The origin of TGCTs can be traced back to primordial
germ cells that fail to mature during embryonic development.
These cells express high levels of pluripotency factors,
including the transcription factor NANOG which is highly
expressed in TGCTs. Gain or amplification of the NANOG locus is
common in advanced tumours, suggesting a key role for this
master regulator of pluripotency in TGCT stemness and
malignancy. METHODS: In this study, we analysed the expression
of microRNAs (miRNAs) that are regulated by NANOG in TGCTs via
integrated bioinformatic analyses of data from The Cancer Genome
Atlas and NANOG chromatin immunoprecipitation in human embryonic
stem cells. Through gain-of-function experiments, MIR9-2 was
further investigated as a novel tumour suppressor regulated by
NANOG. After transfection with MIR9-2 mimics, TGCT cells were
analysed for cell proliferation, invasion, sensitivity to
cisplatin, and gene expression signatures by RNA sequencing.
RESULTS: For the first time, we identified 86 miRNAs regulated
by NANOG in TGCTs. Among these, 37 miRNAs were differentially
expressed in NANOG-high tumours, and they clustered TGCTs
according to their subtypes. Binding of NANOG within 2 kb
upstream of the MIR9-2 locus was associated with a negative
regulation. Low expression of MIR9-2 was associated with tumour
progression and MIR9-2-5p was found to play a role in the
control of tumour stemness. A gain of function of MIR9-2-5p was
associated with reduced proliferation, invasion, and sensitivity
to cisplatin in both embryonal carcinoma and seminoma tumours.
MIR9-2-5p expression in TGCT cells significantly reduced the
expression of genes regulating pluripotency and cell division,
consistent with its functional effect on reducing cancer
stemness. CONCLUSIONS: This study provides new molecular
insights into the role of NANOG as a key determinant of
pluripotency in TGCTs through the regulation of MIR9-2-5p, a
novel epigenetic modulator of cancer stemness. Our data also
highlight the potential negative feedback mediated by MIR9-2-5p
on NANOG expression, which could be exploited as a therapeutic
strategy for the treatment of TGCTs.},
keywords = {Differentiation, MIR-9, NANOG, Pluripotency, stemness, Testicular germ cell tumours},
pubstate = {published},
tppubtype = {article}
}
A part of the University of Nottingham
© 2026 Optics and Photonics at Nottingham. Created for free using WordPress and Kubio